Diabetes and advanced glycation endproducts
The DOI matches its Crossref record; 221 of the 221 references it cites were found in a registry or an index.
Abstract
Vlassara H, Palace MR (Department of Geriatrics, Division of Experimental Diabetes and Ageing, Mount Sinai School of Medicine, and Department of Medicine, Division of Endocrinology, Mount Sinai School of Medicine, NY, USA). Diabetes and Advanced Glycation Endproducts. J Intern Med 2002; 251: 87–101. Bio‐reactive advanced glycation endproducts (AGE) alter the structure and function of molecules in biological systems and increase oxidative stress. These adverse effects of both exogenous and endogenously derived AGE have been implicated in the pathogenesis of diabetic complications and changes associated with ageing including atherosclerosis, renal, eye and neurological disease. Specific AGE receptors and nonreceptor mechanisms contribute to these processes but also assist in the removal and degradation of AGE. The final disposal of AGE depends on renal clearance. Promising pharmacologic strategies to prevent AGE formation, reduce AGE toxicity, and/or inactivate AGE are under investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–221 of 221
Hammes, H., Wellensiek, B., Klöting, I., Sickel, E., Bretzel, R. G., & Brownlee, M. (1998) · Diabetologia · doi:10.1007/s001250050885 · Cited by 60
Systemic arterial compliance is reduced in young patients with IDDM
Berry, K. L., Skyrme-Jones, R. A. P., Cameron, J. D., O’Brien, R. C., & Meredith, I. T. (1999) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1999.276.6.h1839 · Cited by 60
Stitt, A. W., Burke, G. A., Chen, F., McMullen, C. B. T., & Vlassara, H. (2000) · The FASEB Journal · doi:10.1096/fj.00-0289fje · Cited by 56
Self-citationMizutani, K.-I., Ikeda, K., Tsuda, K., & Yamori, Y. (2002) · Journal of Hypertension · doi:10.1097/00004872-200208000-00024 · Cited by 54
Paradoxical Impact of Antioxidants on Post-Amadori Glycoxidation
Culbertson, S. M., Vassilenko, E. I., Morrison, L. D., & Ingold, K. U. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305099200 · Cited by 52
Pharmacokinetics of thiamine derivatives especially of benfotiamine.
Loew, D. (1996) · PubMed · Cited by 51
Carbonyl Stress and Diabetic Complications
Miyata, T., Ishikawa, N., & de Strihou, C. V. Y. (2003) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2003.178 · Cited by 49
Advanced glycation end-products in diabetic nephropathy
Sugiyama, S., Miyata, T., Horie, K., Iida, Y., Tsuyuki, M., TANAKA, H. L., & Maeda, K. (1996) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/11.supp5.91 · Cited by 47
Gugliucci, A., & Bendayan, M. (1995) · Journal of Histochemistry & Cytochemistry · doi:10.1177/43.6.7769229 · Cited by 45
Matsumoto, K., Ikeda, K., Horiuchi, S., Zhao, H., & Abraham, E. C. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7744 · Cited by 43
ADP-Ribose in Glycation and Glycoxidation Reactions
Jacobson, E. L., Cervantes-Laurean, D., & Jacobson, M. K. (1997) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-8632-0_49 · Cited by 42
Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats
Hammes, H., Ali, S. S., Uhlmann, M., Weiss, A., Federlin, K., Geisen, K., & Brownlee, M. (1995) · Diabetologia · doi:10.1007/bf00400629 · Cited by 42
Genome Organization of Human 48-kDa Oligosaccharyltransferase (DDOST)
Yamagata, T., Tsuru, T., Momoi, M. Y., Suwa, K., Nozaki, Y., Mukasa, T., Ohashi, H., Fukushima, Y., & Momoi, T. (1997) · Genomics · doi:10.1006/geno.1997.4966 · Cited by 39
Effects of advanced glycation end-product inhibition and cross-link breakage in diabetic rats
Oturai, P., Christensen, M., Rolin, B., et al. (2000) · Metabolism · doi:10.1053/meta.2000.7731 · Cited by 34
DOLHOFER, R., Lechner, B., & Gerbitz, K.-D. (1996) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.1996.34.4.355 · Cited by 29
Hu, J., Wallensteen, M., & Gennser, G. M. (1996) · Ultrasound in Medicine & Biology · doi:10.1016/0301-5629(96)00040-3 · Cited by 28
Effects of Epalrestat, an Aldose Reductase Inhibitor, on Diabetic Neuropathy and Gastroparesis
Okamoto, H., NOMURA, M., Nakaya, Y., Uehara, K., Saito, K., KIMURA, M., CHIKAMORI, K., & Ito, S. (2003) · Internal Medicine · doi:10.2169/internalmedicine.42.655 · Cited by 27
The role of endothelium in the pathogenesis of diabetic microangiopathy
Selva, M. L., Beltramo, E., Passera, P., Porta, M., & Molinatti, G. M. (1993) · Acta Diabetologica · doi:10.1007/bf00569929 · Cited by 27
Nakamura, N., Yamazaki, K., Satoh, A., Urakaze, M., Kobayashi, M., Yamabe, H., Osawa, H., Shirato, K.-I., Sugawara, T., Nakamura, M., et al. (2003) · PubMed · Cited by 25
Xie, H., & Bevan, J. A. (1999) · Stroke · doi:10.1161/01.str.30.11.2423 · Cited by 21
Schwedler, S. B., Verbeke, P., Bakala, H., Weiss, M. F., Vilar, J., Depreux, P., Fourmaintraux, É., Striker, L. J., & Striker, G. E. (2001) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2001.00096.x · Cited by 20
Cited by
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Advanced glycation endproducts—role in pathology of diabetic complications
Ahmed, N. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.09.004 · Cited by 1,455
Understanding RAGE, the receptor for advanced glycation end products
Bierhaus, A., Humpert, P. M., Morcos, M., Wendt, T., Chavakis, T., Arnold, B., Stern, D. M., & Nawroth, P. P. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0688-7 · Cited by 1,297
Role of advanced glycation end products in cellular signaling
Ott, C., Jacobs, K., Haucke, E., Navarrete Santos, A., Grune, T., & Simm, A. (2014) · Redox Biology · doi:10.1016/j.redox.2013.12.016 · Cited by 1,150
“There exist strong evidence that under basal conditions AGE-R1/OST-48 and AGE-R3/galectin-3 have a high affinity to bind AGEs [131].”
BackgroundAdvanced glycoxidation end products in commonly consumed foods
Goldberg, T., Cai, W., Peppa, M., Dardaine, V., Baliga, B. S., Uribarri, J., & Vlassara, H. (2004) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2004.05.214 · Cited by 744
“dvanced glycoxidation end products (AGEs) constitute a group of heterogeneous moieties produced endogenously from the nonenzymatic glycation of proteins, lipids, and nucleic acids ( 1 ,2).”
BackgroundSelf-citation
Metadata
- Authors
- Vlassara, H., & Palace, M. R.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2002-02
- Volume
- 251
- Issue
- 2
- Pages
- 87-101
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W2084536221
- Cited by
- 697
- References
- 221
- FWCI
- 22.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.